News Hub | News Direct

All Industries


Article thumbnail News Release

Holiday Gift Guide: Add These Luxury Cannabis Items to Your Shopping List

MJ Attaché

Cannabis is legal in 38 states and counting for medical use. Almost 40% of women over the age of 21 currently consume cannabis, and men are nearly twice as likely to use cannabis than women. Odds are, your holiday gift-giving list includes an herbalist who would cherish an easy and elegant addition to their self-care ritual. “Whether the cannabis connoisseur on your holiday giving list uses cannabis medicinally or recreationally, MJ Attaché gift options elevate the experience and simplify the lives of discerning herbal enthusiasts,” explains MJ Attaché founder Christy Fuicelli. “Not only are our attachés statement pieces for self-care rituals, but they’re discreet, lockable and customizable to suit individual consumption needs.” New-to-market, MJ Attaché luxury holiday gift options for cannabis enthusiasts The Anthony Bag - $2,150.00 The Anthony bag combines style and sophistication for the discerning herbalist. Built by Italian artisans with the finest materials, this attaché dispels outdated stereotypes and elevates self-care rituals with patent-pending technology. It is the first on the market to provide a subtle, smell-disguising, practical and elegant solution to suit a cannabis enthusiast’s lifestyle. Available in five colors, The Anthony contains a removable rolling tray and magnetic accessories for customizable storage of your cannabis and accouterments. Retractable Vape Pen Holder - $150.00 Give the gift of ease, and the herbalist on your list will never lose another vape pen. Made in Italy of metal, leather and elastic, this accessory ensures the safekeeping and easy access of a favorite pen. The branded snap hook clips to bags or clothing, and the monogrammed retractable piece allows for use without removal. Fits most batteries up to.5″ in diameter. Retractable Lighter Holder - $175.00 Place this holder under the tree, and your favorite cannabis enthusiast’s lighter will always be at hand. Like the pen holder, this lighter holder is made in Italy of metal and leather. It is engineered to ensure a lighter’s safekeeping and easy access. The accessory’s branded snap hook clips to clothing or bags for accessibility, and the monogrammed retractable piece allows for use without removal. Fits classic BIC lighter. “Our vape pen and lighter holders keep your cannabis accessories safe and right where you need them. The Anthony is a luxury storage solution for all your cannabis needs—making it the perfect gift for a sophisticated herbal enthusiast,” says Fuicelli. “In addition to beauty and refinement, The Anthony is equally functional in that the components can be customized to meet individual needs. For example, edibles, flower and prerolls can be stored in the provided smell-proof jars and locked in The Anthony bag for safekeeping and transport this holiday season,” Fuicelli explains. The Anthony bag makes cannabis self-care rituals easy and elegant Discreet, smell-disguising design you can take anywhere Patent-pending modular elements include smell-proof jars for edibles and flower, lighter holder and glass holder Removable rolling tray for ease of use and clean-up Zipper lock eliminates need for difficult-to-open childproof containers "The Anthony bag not only keeps all my sesh products nicely organized for on-the-go, but it also turns heads. All my colleagues are shocked to find out its purpose!" says Arend Richard, The Anthony bag purchaser and founder of Cirrus Social Club in Denver. Find holiday luxury at MJAttache.com. Connect on Facebook and Instagram for the latest updates and deals. # # # About MJ Attaché Launched in April 2024, MJ Attaché is a designer and developer of high-quality, handmade Italian leather bags and accessories for the cannabis connoisseur. The luxury brand, with its moniker “MJ” (short for Mary Jane—an alias for marijuana), was founded by entrepreneur Christy Fuicelli, a stylish herbalist. Realizing a void in the marketplace, Fuicelli created MJ Attaché to cache and carry her cannabis in a discreet manner reflective of the luxury she enjoyed in other personal products. Fuicelli spent years designing beautifully crafted bags that embody elevated style, sophistication, high quality and fine craftsmanship. Appealing to men and women alike, MJ Attaché products bring ease and style to the cannabis industry and challenge outdated stigmas. Contact Details MJ Attaché Katie Converse for MJ Attaché info@mjattache.com Company Website https://mjattache.com/

October 03, 2024 01:00 PM Mountain Daylight Time

Image
Article thumbnail News Release

PathAI Announces Collaboration with the Crohn’s & Colitis Foundation to Advance Novel IBD Research and Development

PathAI

PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced a partnership with the Crohn’s & Colitis Foundation. The collaboration will empower academic and biopharmaceutical researchers to unlock insights into inflammatory bowel disease (IBD) through the unique combination of quantitative histopathology data and well-characterized multi-modal clinical and molecular data. Quantitative histopathology data will be derived from the deployment of PathAI's IBD Explore ™ and AIM-HI UC ™ algorithm products 1 on digitized histology images from the Crohn’s and Colitis Foundation’s IBD Plexus ​Ⓡ dataset. The parties will also pursue collaborative research using their complementary assets aimed at advancing the field of IBD research.​ Despite the current array of treatment options in ulcerative colitis and Crohn’s disease, remission rates in induction trials are still less than 50%, revealing a therapeutic ceiling in the treatment of both diseases and potential challenges that need to be addressed 2-5. PathAI’s IBD Explore algorithm utilizes AI-powered histopathology analysis to provide detailed insights into the tissue’s inflammatory microenvironment. IBD Explore has the potential to lead to the discovery of novel biomarkers 6,7, disease subtypes, and treatment targets. Meanwhile, AIM-HI UC is the only AI-powered Geboes scoring tool that provides automated subgrade-level scores to accurately and reproducibly measure histological stage and improvement for ulcerative colitis research and clinical trials. “We are thrilled to collaborate with the Crohn’s & Colitis Foundation, the leading nonprofit organization in the IBD space, as a preferred partner to meaningfully advance our understanding of IBD through this unique combination of datasets,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “By partnering with PathAI, we aim to uncover valuable insights from well-characterized pathology images, enhancing our understanding of IBD at the microscopic level and paving the way for novel biomarkers, refined disease subtypes, and potential therapeutic targets,” said Angela Dobes, SVP IBD Plexus, Crohn’s & Colitis Foundation. By combining IBD Plexus’ deeply curated multimodal data, including its large-scale digitized pathology archive, with advanced AI analysis by PathAI, this collaboration aims to enhance researchers’ understanding of the histological factors of IBD to drive novel discoveries that improve quality of life for the millions of Americans living with these diseases. For more information on licensing a joint dataset from PathAI and the Crohn’s and Colitis Foundation, please reach out to bd@pathai.com. Register for a free demo of PathAI’s algorithm products here. Footnotes IBD Explore and AIM-HI UC are For Research Use Only. Not for use in diagnostic procedures. Danese S. et al. Unmet medical needs in ulcerative colitis: an expert group consensus. Dig. Dis. 2019;37(4):266–283. doi: 10.1159/000496739. https://www.ncbi.nlm.nih.gov/pubmed/30726845 Colombel J.F. et al. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut. 2017;66(12):2063–2068. doi: 10.1136/gutjnl-2016-312307. https://www.ncbi.nlm.nih.gov/pubmed/27590995 Colombel J.F. et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779–2789. doi: 10.1016/S0140-6736(17)32641-7. Alsoud D. et al. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021;6(7):589–595. doi: 10.1016/S2468-1253(21)00065-0. Shamshoian et al. 2024. United European Gastroenterology Week. ePoster PP0375. Griffin et al. 2024. European Crohn’s and Colitis Organisation. P008. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples, with the potential to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI is headquartered in Boston, MA. For more information, please visit www.pathai.com. About the Crohn’s & Colitis Foundation The Crohn’s & Colitis Foundation is the leading nonprofit organization focused on both research and patient support for inflammatory bowel disease (IBD), with the mission of curing Crohn’s disease and ulcerative colitis and improving the quality of life for the millions of people living with IBD. The Foundation’s work is dramatically accelerating the research process, while also providing extensive educational and support resources for patients and their families, medical professionals, and the public. To learn more about the IBD Plexus program, visit www.crohnscolitisfoundation.org/research/plexus. Contact Details SVM Public Relations and Marketing Communications +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

October 03, 2024 10:00 AM Eastern Daylight Time

Article thumbnail News Release

Intus Care Announces Launch of CareHub, an Integrated EMR System for PACE

Intus Care

Intus Care, a technology leader in the PACE market, will be previewing CareHub at the 2024 National PACE Association (NPA) Annual Conference in San Diego October 13-16. The product, set for an availability in 2025, is the one-stop-shop EMR and practice management system for workflows to manage PACE’s value-based care model, revolutionizing how interdisciplinary care teams, quality, and compliance managers care for older adults with complex healthcare needs. CareHub by Intus Care is modernizing the technology stack for complex care delivery. For the first time, PACE programs will have a value-based care management system for interdisciplinary care teams (IDT) to: Automate their tedious tasks in a single interface Harness generative artificial intelligence to ease the burden of documentation Access insights through predictive analytics to prioritize their daily workflows Leverage bidirectional data infrastructure for next generation interoperability With several customers already signed on, Intus Care is opening the implementation list for additional partners in 2025. Attendees at NPA 2024 will get an exclusive first look at the innovative features and capabilities that make CareHub the partner for the model of care. Enabling PACE & Building Momentum for 2025 with CareHub During the NPA 2024 event, Intus Care will showcase CareHub, allowing attendees to experience the platform and services available designed to improve staffing efficiency, communication, and patient care. This demo offers an early glimpse into how the product will partner with programs when it officially launches in 2025. “As a natural evolution from our Population Health Analytics and Integrated Care Services products, CareHub addresses three critical unmet needs in the PACE community, which are prevalent across value-based care systems. These needs include reducing staff documentation and administrative burden, integrating disparate data systems, and enabling actionable workflows for interdisciplinary care teams to provide high-quality participant care,” says Robbie Felton, CEO at Intus Care. The NPA 2024 event provides Intus Care with the opportunity to introduce CareHub alongside its suite of existing products. CareHub is the orchestration of comprehensive care management, data driven insights, and integrated workflow solutions. Key examples include EMR, CRM, and Intus Care’s IRIS and Population Health Analytics tools with more to come. Innovating through Deep Partnership with PACE Partners In order to ensure CareHub deeply meets the needs of the PACE community, Intus Care has collaborated with 18 PACE organizations, representing nearly 20,000 participants across the country, as part of its CareHub Product Steering Committee. Through a series of virtual and in-person focus groups, Intus Care gained invaluable insights into the challenges faced by every discipline using CareHub. These sessions have addressed key areas such as IDT coordination, task management, quality and compliance, CMS and state reporting, and health plan management analytics. This deep collaboration has shaped each module, ensuring CareHub is designed to streamline workflows and meet the specific needs of PACE programs. The company is excited to showcase the result of these impactful partnerships. Streamline IDT Coordination through Integrated Workflow Solutions CareHub is uniquely built for interdisciplinary workflows, with an IDT huddle tool and 360-degree view of patient information including clinical and non-clinical insights through a single platform. IDT Morning Meeting AI Intus Suggestions Assessments Care Planning Comprehensive Care Management to Optimize Clinical Outcomes The integrated, easy-to-use modules make it easy for team members to collaborate, communicate, and document so participants receive the right care at the right time. Task Management Notes Scheduling Transportation Patient History Enable Quality, Compliance, and Health Plan Management through Tech Modernization CareHub enhances service coordination with comprehensive compliance tracking and reporting capabilities, including robust tools for claims processing, audits, billing, and authorizations. SDAGs Enrollments Disenrollments Reporting Authorizations What to Expect in 2025 When CareHub launches in 2025, it will offer a care orchestration platform that ensures that complex care for older adults is efficient, compliant, and centered around value-based care outcomes. For more information and to schedule a demo or consultation, reach out through Intus Care’s website. About Intus Care Intus Care creates technology and services for PACE and value-based care organizations to achieve operational efficiency and better clinical and financial outcomes. Intus Care currently works with over 60 PACE programs across 16 states. Visit our website to learn more intuscare.com. Contact Details SVM Public Relations +1 401-490-9700 intuscare@svmpr.com Company Website https://www.intuscare.com/

October 03, 2024 10:00 AM Eastern Daylight Time

Article thumbnail News Release

Direxion Launches Netflix and Taiwan Semiconductor Manufacturing Single Stock Leveraged and Inverse ETFs

Direxion

Furthering their continued success with Single Stock Leveraged and Inverse ETFs, Direxion, a leading provider of tradeable and thematic ETFs, today announced the launch of two additional pairs. These four funds allow active traders to obtain magnified, or inverse, exposure to the daily performance of the common stock of Netflix, Inc., or Taiwan Semiconductor Manufacturing Co., Ltd., through either the Direxion Daily NFLX Bull 2X Shares ( Ticker: NFXL ) and Direxion Daily NFLX Bear 1X Shares ( Ticker: NFXS ), or the Direxion Daily TSM Bull 2X Shares ( Ticker: TSMX ) and Direxion Daily TSM Bear 1X Shares ( Ticker: TSMZ ). “Direxion launched its first two pairs of single stock leveraged and inverse ETFs just over two years ago, amassing more than $3 billion in the expanding suite since,” said Direxion Managing Director, Edward Egilinsky. “Netflix and Taiwan Semiconductor Manufacturing are two of the hottest names in the retail space, lending themselves well to tactical trading in response to potential company events and market sentiment. We look forward to expanding our suite of single stock leveraged and inverse ETFs in the near future.” As ground-breaking products built for active traders, Direxion’s pairs of single stock leveraged and inverse ETFs are meant to be used for short-term trading purposes. Leveraged and inverse single stock ETFs should not be viewed as buy and hold investments, but rather trading tools for traders with a high risk tolerance. In addition, unlike traditional ETFs, or even other levered and/or inverse ETFs, these ETFs track the price of a single stock rather than an index, eliminating the benefits of diversification. All Direxion leveraged and inverse ETFs are intended only for investors with an in-depth understanding of the risks associated with seeking leveraged investment results, and who plan to actively monitor and manage their positions. There is no guarantee these ETFs will meet their objective. Please visit the Direxion Leveraged and Inverse ETF Education Center, where you will find educational brochures, videos, and a self-paced online course to help you understand if leveraged ETFs are right for you. About Direxion: Direxion equips investors who are driven by conviction with ETF solutions built for purpose and fine-tuned for precision. These solutions are available for a broad spectrum of investors, whether executing short-term tactical trades, or investing in thematic strategies. Direxion’s reputation is founded on developing products that precisely express market perspectives and allow investors to manage their risk exposure. Founded in 1997, the company has approximately $48.6 billion in assets under management as of September 30, 2024. For more information, please visit www.direxion.com. There is no guarantee that the Funds will achieve their investment objectives. For more information on all Direxion Shares ETFs, go to www.direxion.com, or call us at 866.301.9214. An investor should carefully consider a Fund’s investment objective, risks, charges, and expenses before investing. A Fund’s prospectus and summary prospectus contain this and other information about the Direxion Shares. To obtain a prospectus and summary prospectus call 866-476-7523 or visit our website at direxion.com. A Fund’s prospectus and summary prospectus should be read carefully before investing. Investing in the funds involves a high degree of risk. Unlike traditional ETFs, or even other leveraged and/or inverse ETFs, these leveraged and/or inverse single stock ETFs track the price of a single stock rather than an index, eliminating the benefits of diversification. Leveraged and inverse ETFs pursue daily leveraged investment objectives, which means they are riskier than alternatives which do not use leverage. They seek daily goals and should not be expected to track the underlying stock’s performance over periods longer than one day. They are not suitable for all investors and should be utilized only by investors who understand leverage risk and who actively manage their investments. The Funds will lose money if the underlying stock’s performance is flat, and it is possible that the Bull Fund will lose money even if the underlying stock’s performance increases, and the Bear Fund will lose money even if the underlying stock’s performance decreases, over a period longer than a single day. An investor could lose the full principal value of his or her investment in a single day. Investing in the Funds is not the same as investing directly in NFLX or TSM. Entertainment Industry Risk — Companies in the entertainment industry may be impacted by the high costs of research and development of new content and services in an effort to stay relevant in a highly competitive industry, and entertainment products may face a risk of rapid obsolescence. Entertainment companies are subject to risks that include cyclicality of revenues and earnings, changing tastes and topical interests, and decreases in the discretionary income of their targeted consumers. Consumer Discretionary Sector Risk — Because companies in the consumer discretionary sector manufacture products and provide discretionary services directly to the consumer, the success of these companies is tied closely to the performance of the overall domestic and international economy. Semiconductor Industry Risk – Semiconductor companies may face intense competition, both domestically and internationally, and such competition may have an adverse effect on such companies’ profit margins. Semiconductor companies may have limited product lines, markets, financial resources or personnel. Companies in the semiconductor industry may have products that face obsolescence due to rapid technological developments and frequent new product introduction, unpredictable changes in growth rates and competition for qualified personnel. Netflix, Inc. Investing Risk – Issuer-specific attributes may cause an investment held by the Fund to be more volatile than the market generally. The value of an individual security or particular type of security may be more volatile than the market as a whole and may perform differently from the value of the market as a whole. As of the date of this prospectus, in addition to the risks associated with companies in the consumer discretionary sector, and more specifically the entertainment industry, Netflix, Inc. faces risks related to maintaining and expanding membership for its streaming services; competition in the entertainment video market; unforeseen costs or liability in connection with content that is acquired, produced, licensed and/or distributed through its service; the ability to manage change and growth in its business; costs and challenges associated with strategic acquisitions and investments; regulatory changes and legal issues; protecting its intellectual property; consumer data privacy issues; and network operators handling and changing data access. Taiwan Semiconductor Manufacturing Co., Ltd. Investing Risk – Issuer-specific attributes may cause an investment held by the Fund to be more volatile than the market generally. The value of an individual security or particular type of security may be more volatile than the market as a whole and may perform differently from the value of the market as a whole. As of the date of this prospectus, in addition to the risks associated with companies in the semiconductor sector, TSM faces risks associated with: the highly competitive nature of the semiconductor industry; economic and market uncertainty; reductions in demand for its products; potential concentration of revenues in a few large clients; geopolitical events and pandemics; adequate protection of technology or other intellectual property; exchange rates; reliance on third parties to manufacture products; possible shortages of equipment or materials needed to manufacture products; cybersecurity attacks and data breaches; system failures or outages; potential incompatibility of product with some or all industry standard software and hardware; increases in costs; adverse government regulations; regulatory compliance costs; litigation; taxes; indebtedness; and the ability to attract and retain high quality talent. Direxion Shares Risks – An investment in each Fund involves risk, including the possible loss of principal. Each Fund is non-diversified and includes risks associated with a Fund concentrating its investments in a particular security, industry, sector, or geographic region which can result in increased volatility. A Fund's investments in derivatives such as futures contracts and swaps may pose risks in addition to, and greater than, those associated with directly investing in securities or other investments, including imperfect correlations with underlying investments or the Fund's other portfolio holdings, higher price volatility and lack of availability. As a result, the value of an investment in a Fund may change quickly and without warning. Risks of the Funds include Effects of Compounding and Market Volatility Risk, Derivatives Risk, Counterparty Risk, Rebalancing Risk, Intra-Day Investment Risk, Netflix, Inc. or Taiwan Semiconductor Manufacturing Co., Ltd. Investing Risk, Market Risk, Industry Concentration Risk, Cash Transaction Risk, Indirect Investment Risk, and risks specific to the consumer discretionary sector, entertainment industry or semiconductor industry. Additional risks include, for the Direxion Daily NFLX Bull 2X Shares and Direxion Daily TSM Bull 2X Shares, Leverage Risk and Daily Correlation Risk, and for the Direxion Daily NFLX Bear 1X Shares and Direxion Daily TSM Bear 1X Shares, Shorting or Inverse Risk as well as Daily Inverse Correlation Risk. Please see the summary and full prospectuses for a more complete description of these and other risks of the Funds. Distributor: ALPS Distributors, Inc. Contact Details Ditto Public Relations Danielle Black, AD direxion@dittopr.co Company Website https://www.direxion.com/

October 03, 2024 09:00 AM Eastern Daylight Time

Article thumbnail News Release

This Company Is Taking An Innovative, Non-Opioid Approach To Pain Management For Pancreatic Cancer

Autonomix Medical, Inc.

By Austin DeNoce, Benzinga Pancreatic cancer is one of the most aggressive and painful forms of cancer, often leaving patients with limited options for effective pain management. Traditional treatments like opioids and nerve blocks offer only temporary relief, and their side effects can further diminish the quality of life. This underscores the urgent need for innovative solutions that can provide sustainable pain relief for those battling this debilitating disease. Autonomix Medical (NASDAQ: AMIX) is working to address this critical gap with a novel, non-opioid approach designed to significantly reduce pain in pancreatic cancer patients. The company recently shared promising preliminary data from its ongoing human clinical trial, showcasing the potential of its precision nerve-targeted treatment. This minimally invasive method aims to deliver lasting pain relief, offering hope to patients who have struggled to find effective alternatives to around-the-clock opioids. “We are encouraged by the significant, sustained pain reduction demonstrated from the lead-in patients in our ongoing first-in-human trial. These are very sick individuals, who up until this point primarily relied on opioids to help mitigate their pain, which our baseline data shows were not effective,” said Autonomix CEO Brad Hauser. Overview Of Preliminary Results In early September, Autonomix announced positive outcomes from its proof-of-concept trial. The results indicated that 60% of patients in the initial cohort experienced a substantial reduction in pain. Using the Visual Analog Scale (VAS), patients reported a dramatic drop in pain scores from an average of 8.0 to just 1.33 within 4 to 6 weeks post-procedure — an 83% reduction. Significantly, patients in the responder group felt pain relief as early as one day after the procedure, highlighting the potential for rapid and meaningful impact. The trial also identified a key factor that may factor in treatment success: the access point used during the procedure. Patients treated through femoral access showed significant improvements, while those with brachial access did not. These findings suggest that the method of delivery may play a crucial role in optimizing outcomes. Innovative Technology Behind The Treatment Autonomix reports that its groundbreaking technology employs a catheter-based microchip sensing array capable of detecting and differentiating nerve signals with extraordinary precision – up to 3,000 times greater than existing methods. The company says this advanced platform not only identifies overactive nerve signals but also targets them with radiofrequency (RF) ablation, providing precise pain relief without the common drawbacks of conventional treatments. Looking Ahead: Expanding The Possibilities The trial is expected to complete patient enrollment by the end of 2024, with plans to incorporate additional biomarkers to refine the correlation between nerve ablation and pain relief. The success of this trial could pave the way for a new standard in pain management, extending beyond pancreatic cancer to other conditions characterized by severe nerve-related pain. A Potential Game-Changer, Non-Opioid Approach In Pain Therapy Autonomix Medical could be poised to help revolutionize pain management, not only for pancreatic cancer patients but for a broader range of chronic pain conditions. As their technology evolves and clinical trials progress, the company says its approach could transform the landscape of pain therapy, offering hope and improved quality of life to countless individuals. By developing cutting-edge solutions, Autonomix is not just addressing a critical unmet need but also potentially setting the stage for a new era in precision pain management. With the potential to impact a significant segment of the multi-billion-dollar pain management market, this breakthrough could mark a turning point in the way we treat pain in complex medical conditions. Featured photo by Ousa Chea from Unsplash. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum. Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the completion of patient enrollment in the trial and the Company’s ability to successfully meet the milestones set forth in this press release on a timely basis, if at all. Such forward-looking statements can be identified by the use of words such as ‘should,’ ‘may,’ ‘intends,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘forecasts,’ ‘expects,’ ‘plans,’ and ‘proposes.’Although Autonomix Medical, Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering circular filed with the U.S. Securities and Exchange Commission (“SEC”) on January 26, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details JTC Team, LLC autonomix@jtcir.com Company Website https://autonomix.com/

October 03, 2024 08:35 AM Eastern Daylight Time

Image
Article thumbnail News Release

Transforming Gaming-Related Transactions: How Gameflip Is Empowering A New Generation Of Gamers

Benzinga

By Josh Enomoto, Benzinga Even within a robust and burgeoning ecosystem like the global video game industry, inefficiencies exist. For gamers, connectivity has offered many advantages, enabling access and opportunities. However, the decentralization of data has come at the cost of trust or lack thereof. This is where gaming-centric marketplace Gameflip enters the playing field. Leveraging a secure and intuitive platform, Gameflip allows users to buy, sell and trade digital goods. At its core, Gameflip’s “why” centers on empowerment. Gone are the days of unconnected console-based devices. Contemporary digital entertainment involves global communities and marketplaces. With in-game assets such as character skins, outfits and rare items that often command real-world value, an industry for gaming-related commerce has developed. However, growth brings risks – prospects for financial viability tend to attract nefarious elements. Gameflip seeks to address this pain point with its secure, efficient and community-driven environment. The company’s ethos aims at building trust, simplifying transactions and expanding the functionality of in-game items. Effectively, Gameflip seeks to be the leading marketplace of the video game industry, marrying contemporarily relevant goods with a rapidly expanding community. Creating A Venture For A Whole New Paradigm No longer operating in isolation, today’s games foster connectivity and community. With that comes the desire – and subsequently an economic demand – for in-game assets. Based on information compiled by Statista, 29% of U.S. adults aged 18-to-29-year spent one to five hours a week playing video games. The next highest ratio was 21%, which described young adults in the aforementioned cohort playing six to 10 hours. Put another way, members of Generation Z count video games among their priorities. It’s an essential component of youth culture, and demand for in-game items that enhance the overall experience is rising. That’s one of the central catalysts for why Gameflip entered the domain. As Benzinga writer Caleb Naysmith articulated, the company opened a market for digital assets that were siloed within the confines of their underlying games. By providing a solution for gamers to transact their digital goods, Gameflip has created a platform that accommodates transactions for digital gaming items and assets. And some savvy gamers are already raking in hundreds of thousands on the platform by selling their gaming assets for top dollar. Another factor to consider is the rise of so-called freemium or free-to-play titles. While these offerings technically require no upfront cost to play, their inclusion of in-game purchases or microtransactions provides the ability to boost player engagement and enjoyment. Even better, 82% of American gamers have done exactly that – make in-game purchases in freemium titles. As such, the demand is real. Gameflip aims to distinguish itself by connecting buyers and sellers in a safe, secure environment. Feeding Demand The Responsible Way As of this writing, Gameflip has sold nearly 13.6 million items. Since launching the platform in 2015, the company boasts over $180 million in sales, three million app downloads, more than 40 million item listings and a community that has exceeded the seven-million user mark. If that wasn’t enough, the enterprise has raised over $10 million from venture capitalists. Part of this success focuses on youth. The amount of young children playing video games has grown exponentially. While that’s a net positive for the broader gaming sector, this dynamic poses a significant challenge in terms of safety. As industry experts point out, the surge in popularity has also translated to exposure to online gaming fraud. Children are especially vulnerable targets, presenting huge concerns for parents. What makes Gameflip stand out is its guarantee. All purchases are encrypted and enjoy the protection of a 100% cash-back guarantee. Should a problem arise, a buyer can simply report the issue and the company will step in to resolve the matter. Of course, fraud is often a two-way street. Gameflip also protects sellers on its platform through a variety of mechanisms, including escrowed payments, zero chargeback liability and dispute resolution assistance. With robust protections in place, users can buy and sell a broad spectrum of items: games, digital assets, gift cards, movies and more. Empowering A New Era Of Digital Gaming In an environment where digital gaming assets command real economic value, Gameflip has carved out a niche by providing a platform that blends security, community and innovation. Amid the mixture of opportunity and rising security challenges, Gameflip seeks to stand as a trusted solution, ensuring that buyers and sellers alike can transact with confidence. Moreover, the company’s growing user base and commitment to safeguarding transactional integrity underscore a pivotal point. Gameflip isn’t just meeting the current demands of the gaming industry – it’s potentially setting a new standard for the future of digital commerce. Featured photo by George Becker from Pexels. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 03, 2024 08:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game

Benzinga

By Johnny Rice, Benzinga Erez Aminov, CEO & Chairman of the Board, and Dr. Itzchak Angel, Chief Scientific Advisor for MIRA Pharmaceuticals (NASDAQ: MIRA), were recently interviewed by Benzinga. MIRA is a pre-clinical biopharma focused on developing treatments for neurologic and neuropsychiatric disorders. It holds exclusive rights to Ketamir-2, an oral ketamine analog being studied for neuropathic pain, treatment-resistant depression, major depressive disorder with suicidal ideation and PTSD. The company’s other primary asset, MIRA-55, is a novel pharmaceutical marijuana analog that could provide enhanced therapeutic effects over THC. Watch the full interview here: Featured photo by Jeremy Bishop on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 03, 2024 08:25 AM Eastern Daylight Time

Video Image
Article thumbnail News Release

Award-Winning Hair Care Brand Design Essentials Pledges $2 Million to Support Historically Black Colleges and Universities

Design Essentials

Design Essentials, the Atlanta-based Black-owned company leading in premium hair care for nearly 35 years, is proud to contribute $1 million dollars to Spelman College in Atlanta towards the launch of their Cosmetic Science Program, and $1 million dollars to Howard University in Washington D.C. for the creation of The Design Essentials Community Fund. As part of its continued commitment to consumers and future leaders, Design Essentials is leveraging its expertise in healthy haircare practices for all hair types to inspire and give back to the next generation of leaders and innovators. The pledges reflect the brands belief in philanthropy through donations and resources to local and international communities. Design Essentials aims to make a meaningful impact through give-back initiatives focused on community enrichment, education and mentorship, while also serving its professional and consumer network. Improving access to resources that cater to Black women and men for career advancement, the brand is continuing to create inclusive and diverse spaces, along with premium expert-backed products for textured hair. Spelman College is a global leader in the education of women of African descent. The partnership will directly contribute to Spelman’s Cosmetic Science Program – the first-ever major of its kind available at an HBCU (Historically Black College and University). The groundbreaking STEM program offers a culturally relevant approach with unique perspectives from Black women through research and working knowledge of trends and innovations, students will explore the use of cosmetics and personal care products, particularly in communities of African descent. The pledge will impact the innovative research and development of products, connecting future chemists with the core consumer to achieve efficacy and representation in the products they use. Howard University is one of the leading research universities dedicated to educating students from diverse backgrounds. The launch of The Design Essentials Community Fund will pave the way for Howard University School of Business students who aspire to become entrepreneurs and business leaders. Cornell McBride, Jr., President of McBride Research Laboratories, Inc. and a Howard University alumna, credits his business acumen to the success of flagship brand Design Essentials over the past two decades. Students will gain access to business training programs, including business pitch competitions, business plan advisory services, marketing and branding bootcamps, capital-raising modules, and opportunities to learn about new software and technology. “We are incredibly honored to support the future leaders at these HBCUs during this moment in history,” states Cornell McBride Jr., President and Chief Executive Officer of McBride Research Laboratories. As a Howard University alum, McBride Jr. is dedicated to keeping the Design Essentials legacy intact by supporting rising leaders in business and beauty industries. “It has always been our mission to create high-quality products that meet the demand of hairstyling needs, leave a footprint in social impact initiatives, and nurture individuals and scholars who will drive inclusion within the beauty industry. By investing in the first-ever cosmetic science program and ongoing entrepreneurial mentorship and career opportunities, we are reinforcing our commitment to education and ensuring that diverse voices are at the forefront of innovation in our industry.” Design Essentials’ pledge marks the start of a broader effort to support HBCUs at a national level and nurture the connection between multicultural haircare and consumers globally. As a legacy brand, Design Essentials serves as a partner in style, fostering relationships with future leaders and brand fans to achieve styling success. For more information on Design Essentials, please visit www.designessentials.com For additional information on Spelman College’s Cosmetics Science Program, please visit https://www.spelman.edu/academics/cosmetic-science/index.html For more information on Howard University, please visit https://howard.edu/ About Design Essentials Design Essentials is a leading provider of premium hair care solutions with nearly 35 years of experience. The brand offers over 80 curated products for all hair types and textures and is committed to delivering innovative, research-driven solutions that cater to both professional and consumer needs. Design Essentials is proud to be minority-owned and operated, with a global reach and a strong commitment to giving back to communities worldwide. Contact Details First and Last PR Camille Gordon camille@firstandlastpr.com First and Last PR Brooke Bhola brooke@firstandlastpr.com Company Website https://designessentials.com/

October 03, 2024 08:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Focal Chooses SPARK Microsystems’ UWB Wireless Tech for New HiFi DIVA UTOPIA Speakers

SPARK Microsystems

SPARK Microsystems, a Canadian fabless semiconductor company specializing in next-generation short-range wireless communications, today announced its collaboration with Focal, the renowned French audio brand, in the development of the revolutionary DIVA UTOPIA loudspeaker. This collaboration brings together Focal’s expertise in high-fidelity audio with SPARK’s Ultra-Wideband (UWB) technology, delivering a high-performance wireless audio experience. The DIVA UTOPIA is Focal’s first connected, wireless active loudspeaker, designed to meet the demands of those seeking exceptional sound quality with the convenience of modern wireless technology. SPARK’s SR1020 wireless transceiver leverages UWB technology to supply the data transmission between the two speakers, delivering uncompressed audio with ultra-low latency, setting a new standard for wireless audio performance. “Our collaboration with Focal showcases the advantages of SPARK’s UWB in delivering high-resolution audio without the limitations of traditional wireless technologies,” said Julie Delamarre, SPARK Microsystems, Senior Vice President of Worldwide Sales. “The DIVA UTOPIA is a great example of how a UWB wireless connection ensures every note is transmitted with the highest fidelity.” SPARK’s UWB connectivity allows for a seamless wireless connection between the two DIVA UTOPIA loudspeakers, maintaining a stable and lossless signal at 96kHz/24bit resolution. This advanced technology eliminates the need for wires while preserving the quality of sound typically associated with wired connections. With support for major streaming platforms and wireless protocols, the DIVA UTOPIA offers a versatile and intuitive user experience. SPARK’s UWB technology supports multiroom configurations, making it easier than ever to integrate the DIVA UTOPIA into a complete home music ecosystem. "The DIVA UTOPIA represents a new era in high-fidelity audio. By integrating SPARK Microsystems' UWB technology, we have created a loudspeaker that not only delivers exceptional sound quality but also offers the freedom and flexibility that today’s consumers demand,” said Rejean Bedel, Focal & Naim, Group Marketing Manager. “This partnership is a testament to our commitment to pushing the boundaries of innovation and redefining the listening experience." The DIVA UTOPIA loudspeakers are now available exclusively at qualified Focal Powered by Naim stores. For more information, visit Focal's website. About Focal Since 1979, Focal has stood out from the crowd in manufacturing loudspeakers and acoustic speakers. Their expertise extends to headphones, car audio kits, professional speakers, and installations for yachts. This unique know-how, combined with their in-house manufacturing in France, puts Focal among the top audio brands globally. In 2011, Focal joined forces with Naim — the British leader in high-end electronics — under the VerVent Audio group to offer exquisite complete audio systems. Visit www.focal.com for more. About SPARK Microsystems​ SPARK Microsystems is building next generation short-range wireless communication devices. SPARK provides high data rate and very low latency wireless communication links at an ultra-low power profile, making it ideal for personal area networks (PANs) used in mobile, consumer and IoT-connected products. Leveraging patented technologies, SPARK Microsystems strives to minimize and ultimately eliminate wires and batteries from a wide range of applications while delivering a wired-like performance. For more information, please visit www.sparkmicro.com.​ Contact Details Jenna Desimone +1 508-340-6851 jdesimone@rainierco.com Company Website https://www.sparkmicro.com

October 02, 2024 12:03 PM Eastern Daylight Time

Image
12345 ... 3730